Viking Therapeutics, Inc.
9 clinical trials · Sponsor
◉ Watch Viking Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| VK2735 for Weight Management Phase 3 (NCT07104500) | Viking Therapeutics, Inc. | 2025-06-23 |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (NCT07104383) | Viking Therapeutics, Inc. | 2025-06-23 |
| VK2735 for Weight Management Phase 2 (NCT06068946) | Viking Therapeutics, Inc. | 2023-08-31 |
| Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (NCT05203237) | Viking Therapeutics, Inc. | 2021-12-14 |
| A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (NCT04973657) | Viking Therapeutics, Inc. | 2021-06-22 |
| A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (NCT04173065) | Viking Therapeutics, Inc. | 2019-11-15 |
Track Viking Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.